









Markets
/
Stocks
/
nasdaq-dwtx
/

Dogwood Therapeutics Inc

DWTX

5.010USD

+0.196+4.06%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

9.57MMarket Cap

LossP/E TTM



Dogwood Therapeutics Inc

5.010

+0.196+4.06%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

181 / 506

Overall Ranking

295 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

17.000

Target Price

+253.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.

Fairly Valued

The company’s latest PE is -0.25, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 387.60K shares, increasing 12.16% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 11.78K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.60, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.60

Change



Financials

3.57

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.24, which is -2.09% below the recent high of -0.24 and -10.09% above the recent low of -0.27.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 181/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Dogwood Therapeutics Inc is 11.00, with a high of 30.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

17.000

Target Price

+253.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Dogwood Therapeutics Inc

DWTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.49, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 5.15 and the support level at 4.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.49

Change

0.4

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Buy

RSI(14)

55.209

Neutral

STOCH(KDJ)(9,3,3)

46.959

Neutral

ATR(14)

0.177

Low Volatility

CCI(14)

189.095

Buy

Williams %R

36.825

Buy

TRIX(12,20)

0.002

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.895

Buy

MA10

4.885

Buy

MA20

4.895

Buy

MA50

4.859

Buy

MA100

4.938

Buy

MA200

5.180

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 20.28%, representing a quarter-over-quarter decrease of 12.46%. The largest institutional shareholder is The Vanguard, holding a total of 11.78K shares, representing 0.62% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

CK Life Sciences International Holdings, Inc.

211.38K

Orca Capital GmbH

69.82K

Corday (Brian David)

35.30K

-32.95%

Geode Capital Management, L.L.C.

14.41K

+31.79%

The Vanguard Group, Inc.

Star Investors

11.78K

Duncan (Gregory Scott)

2.30K

Tower Research Capital LLC

1.05K

+8.02%

Morgan Stanley Smith Barney LLC

600.00

Keefer (David R)

512.00

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.80. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.